Protean phenotypic features of the A3243G mitochondrial DNA mutation.

TitleProtean phenotypic features of the A3243G mitochondrial DNA mutation.
Publication TypeJournal Article
Year of Publication2009
AuthorsKaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC
JournalArch Neurol
Volume66
Issue1
Pagination85-91
Date Published2009 Jan
ISSN1538-3687
KeywordsAdolescent, Adult, Child, Child, Preschool, Cohort Studies, DNA Mutational Analysis, DNA, Mitochondrial, Early Diagnosis, Female, Genetic Predisposition to Disease, Genetic Testing, Genotype, Heterozygote, Humans, Inheritance Patterns, Male, MELAS Syndrome, Middle Aged, Mutation, Phenotype, Surveys and Questionnaires, Young Adult
Abstract

OBJECTIVE: To describe the spectrum of clinical symptoms, signs, and laboratory features associated with A3243G, a mitochondrial DNA point mutation that affects multiple organs with varying severity, making the diagnosis and treatment of these patients complex.

DESIGN: Cohort study.

SETTING: Columbia University Medical Center.

PARTICIPANTS: A cohort of 123 matrilineal relatives from 45 families, including 45 fully symptomatic patients with mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (syndrome), 78 carrier relatives, and 30 controls.

MAIN OUTCOME MEASURES: Data gathered from standardized medical history questionnaires, neurological and ophthalmological examination forms, and laboratory tests. We compared data between 3 groups.

RESULTS: Mutation carriers' clinical and laboratory results frequently had many abnormalities. In addition to neurological symptoms, they often had cardiac, endocrine, gastrointestinal, and psychiatric symptoms.

CONCLUSIONS: The A3243G mutation carriers have multiple medical problems, suggesting that the A3243G mutation should be considered as an etiological factor in patients with multisystem clinical presentations or a family history compatible with matrilineal inheritance. Because some medical problems affecting A3243G mutation carriers are treatable, early detection and proactive management may mitigate the burden of morbidity.

DOI10.1001/archneurol.2008.526
Alternate JournalArch Neurol
PubMed ID19139304
Grant ListP01 HD032062 / HD / NICHD NIH HHS / United States
P01-HD32062 / HD / NICHD NIH HHS / United States
1 UL1 RR024156 / RR / NCRR NIH HHS / United States
Related Institute: 
MRI Research Institute (MRIRI)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065